Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Weekes

Showing results (21-30 of 70) with videos related to

Pageof 7
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 11, 2012
Pharmacokinetic and pharmacodynamic analysis of circulating biomarkers of anti-NRP1, a novel antiangiogenesis agent, in two phase I trials in patients with advanced solid tumorsYan Xin, Jessica Li, Jenny Wu, et al.
Investigational New Drugs|March 23, 2010
Thymidylate synthase (TYMS) enhancer region genotype-directed phase II trial of oral capecitabine for 2nd line treatment of advanced pancreatic cancerColin D Weekes, Sujatha Nallapareddy, Michelle A Rudek, et al.
The Oncologist|August 25, 2018
A Phase I Dose-Escalation Study of Linsitinib (OSI-906), a Small-Molecule Dual Insulin-Like Growth Factor-1 Receptor/Insulin Receptor Kinase Inhibitor, in Combination with Irinotecan in Patients with Advanced CancerS Lindsey Davis, S Gail Eckhardt, Jennifer R Diamond, et al.
Cancer Medicine|September 3, 2021
Leveraging patient-reported outcomes (PROs) in patients with pancreatic cancer: The Pancreatic Cancer Action Network (PanCAN) online patient registry experienceArjun Gupta, Omar Khalid, Cassadie Moravek, et al.
Oncogene|September 22, 2015
Regulation of osteosarcoma cell lung metastasis by the c-Fos/AP-1 target FGFR1D Weekes, T G Kashima, C Zandueta, et al.
CA: a Cancer Journal for Clinicians|July 20, 2020
Multidisciplinary standards of care and recent progress in pancreatic ductal adenocarcinomaAaron J Grossberg, Linda C Chu, Christopher R Deig, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 5, 2018
First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid TumorsJohn H Strickler, Colin D Weekes, John Nemunaitis, et al.
Clinical and Translational Science|August 2, 2020
A Phase I Study of Dinaciclib in Combination With MK-2206 in Patients With Advanced Pancreatic CancerAdrian G Murphy, Marianna Zahurak, Mirat Shah, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 25, 2024
A Translational Study of the ATR Inhibitor Berzosertib as Monotherapy in Four Molecularly Defined Cohorts of Advanced Solid TumorsGregory M Cote, Bose S Kochupurakkal, Khanh Do, et al.
Investigational New Drugs|May 23, 2018
Phase 1b investigation of the MEK inhibitor binimetinib in patients with advanced or metastatic biliary tract cancerR S Finn, D H Ahn, M M Javle, et al.
Pageof 7

Showing results (21-30 of 70) with videos related to

Sort By:
Pageof 7
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 11, 2012
Pharmacokinetic and pharmacodynamic analysis of circulating biomarkers of anti-NRP1, a novel antiangiogenesis agent, in two phase I trials in patients with advanced solid tumorsYan Xin, Jessica Li, Jenny Wu, et al.
Investigational New Drugs|March 23, 2010
Thymidylate synthase (TYMS) enhancer region genotype-directed phase II trial of oral capecitabine for 2nd line treatment of advanced pancreatic cancerColin D Weekes, Sujatha Nallapareddy, Michelle A Rudek, et al.
The Oncologist|August 25, 2018
A Phase I Dose-Escalation Study of Linsitinib (OSI-906), a Small-Molecule Dual Insulin-Like Growth Factor-1 Receptor/Insulin Receptor Kinase Inhibitor, in Combination with Irinotecan in Patients with Advanced CancerS Lindsey Davis, S Gail Eckhardt, Jennifer R Diamond, et al.
Cancer Medicine|September 3, 2021
Leveraging patient-reported outcomes (PROs) in patients with pancreatic cancer: The Pancreatic Cancer Action Network (PanCAN) online patient registry experienceArjun Gupta, Omar Khalid, Cassadie Moravek, et al.
Oncogene|September 22, 2015
Regulation of osteosarcoma cell lung metastasis by the c-Fos/AP-1 target FGFR1D Weekes, T G Kashima, C Zandueta, et al.
CA: a Cancer Journal for Clinicians|July 20, 2020
Multidisciplinary standards of care and recent progress in pancreatic ductal adenocarcinomaAaron J Grossberg, Linda C Chu, Christopher R Deig, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 5, 2018
First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid TumorsJohn H Strickler, Colin D Weekes, John Nemunaitis, et al.
Clinical and Translational Science|August 2, 2020
A Phase I Study of Dinaciclib in Combination With MK-2206 in Patients With Advanced Pancreatic CancerAdrian G Murphy, Marianna Zahurak, Mirat Shah, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 25, 2024
A Translational Study of the ATR Inhibitor Berzosertib as Monotherapy in Four Molecularly Defined Cohorts of Advanced Solid TumorsGregory M Cote, Bose S Kochupurakkal, Khanh Do, et al.
Investigational New Drugs|May 23, 2018
Phase 1b investigation of the MEK inhibitor binimetinib in patients with advanced or metastatic biliary tract cancerR S Finn, D H Ahn, M M Javle, et al.
Pageof 7